PhaseRx (PhaseRx) Forward Dividend Yield % : 0.00% (As of Jun. 05, 2024)

View and export this data going back to 2016. Start your Free Trial

What is PhaseRx Forward Dividend Yield %?

As of today (2024-06-05), the Forward Annual Dividend Yield of PhaseRx is 0.00%.

As of today (2024-06-05), the Trailing Annual Dividend Yield of PhaseRx is 0.00%.

PZRXQ's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.665
* Ranked among companies with meaningful Forward Dividend Yield % only.

PhaseRx's Dividends per Share for the three months ended in Sep. 2017 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of PhaseRx's Forward Dividend Yield %

For the Biotechnology subindustry, PhaseRx's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PhaseRx's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhaseRx's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where PhaseRx's Forward Dividend Yield % falls into.

PhaseRx Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

PhaseRx (OTCPK:PZRXQ) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

PhaseRx Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of PhaseRx's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

PhaseRx (PhaseRx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseRx Inc (OTCPK:PZRXQ) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119

Website

http://www.phaserx.com

PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.

Executives

Gordon Brandt	officer: Chief Medical Officer	410 WEST HARRISON STREET, SEATTLE WA 98119
Paul H Johnson	director	3450 MONTE VILLA PARKWAY, BOTHELL WA 98053
Peggy V Phillips	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Brian G Atwood	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Schmidt John A Jr	director	300 THIRD ST, CAMBRIDGE X1 02142
Steven Gillis	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Samuel D Colella	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Robert Nelsen	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Rebecca B Robertson	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Barbara N Lubash	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Donald B Milder	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Charles M Warden	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

PhaseRx (PhaseRx) Headlines

From GuruFocus

Stocks Open Higher in Friday Session

By Omar Venerio Omar Venerio • 10-13-2017

PhaseRX: The Latest Pick From a Legendary VC Firm

By $$$ Christopher Malcolm • 05-24-2016